KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
September 09 2021 - 7:30AM
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical
company focused on the discovery and development of proprietary
prodrugs, today announced that Travis C. Mickle, Ph.D.,
President and Chief Executive Officer of KemPharm, will present
virtually at the H.C. Wainwright 23rd Annual Global Investment
Conference taking place September 13-15, 2021. The prerecorded
presentation will be available starting at 9:00 a.m., ET on
September 13, 2021, and can be accessed via the conference’s
virtual platform by registered conference attendees.
Details of the presentation are as follows:
Event: |
H.C. Wainwright 23rd Annual Global Investment Conference |
Date: |
September 13-15, 2021 |
Time: |
Presentations available starting at 9:00 a.m., ET on September 13,
2021 |
Registration: |
https://hcwevents.com/annualconference/ |
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LAT®
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT® technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, stimulant use disorder (SUD) and CNS rare
diseases, including idiopathic hypersomnia (IH). KemPharm’s lead
clinical development candidate for the treatment of SUD, KP879, is
based on its prodrug of d-methylphenidate, known as
serdexmethylphenidate (SDX). In addition, KemPharm has received FDA
approval for AZSTARYSTM, a new once-daily treatment for ADHD in
patents age six years and older, and for APADAZ®, an
immediate-release combination product containing benzhydrocodone, a
prodrug of hydrocodone, and acetaminophen. For more information on
KemPharm and its pipeline of prodrug product candidates visit
www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook
and YouTube.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc.Jason
Rando/Maureen McEnroe, CFA(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024